Specifying a Second-Site GMP Drug Substance Technology Transfer for a Licensed Fc-Fusion Biologic: A Request-for-Proposal Framework for Comparability and Process Validation

A biologic approved under an accelerated pathway can be on the market before its confirmatory evidence is complete, so any manufacturing shortfall becomes a patient-access problem, not a delay in a clinical trial. This article builds the rationale and the request for proposal (RFP) for a technology transfer and process validation campaign that would qualify a second site or a scaled bioreactor train for a hypothetical licensed decoy-receptor Fc-fusion protein produced in Chinese hamster ovary cells. The rationale separates demonstrated facts from sponsor assumptions, treats glycosylation as a process-sensitive quality attribute of the product class, and argues that a second qualified source removes a single point of failure. The RFP specifies a 2,000 L campaign with two engineering runs and three GMP validation lots, an orthogonal comparability panel, dependency-based milestones with an 18 to 20 month duration, a budget of USD 8.7 to 12.15 million, a weighted scoring framework, and the confidentiality and intellectual property protections to put in place before issuing the request.Keywords: request for proposal; Fc-fusion protein; technology transfer; comparability; glycosylation; ICH Q5E; process validation; CDMO

Authors

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24425345
Primary Topic
Viral Infectious Diseases and Gene Expression in Insects
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Specifying a Second-Site GMP Drug Substance Technology Transfer for a Licensed Fc-Fusion Biologic: A Request-for-Proposal Framework for Comparability and Process Validation

Peivand Pirouzi, Perpetua Ulofu, Uchechukwu Veronica Ikechukwu, Yemurayi Hungwe et al.
Zenodo (CERN European Organization for Nuclear Research)
Viral Infectious Diseases and Gene Expression in Insects
article

Specifying a Second-Site GMP Drug Substance Technology Transfer for a Licensed Fc-Fusion Biologic: A Request-for-Proposal Framework for Comparability and Process Validation

Peivand Pirouzi, Perpetua Ulofu, Uchechukwu Veronica Ikechukwu, Yemurayi Hungwe, Precious Chinenye Sunday
article en

Abstract

A biologic approved under an accelerated pathway can be on the market before its confirmatory evidence is complete, so any manufacturing shortfall becomes a patient-access problem, not a delay in a clinical trial. This article builds the rationale and the request for proposal (RFP) for a technology transfer and process validation campaign that would qualify a second site or a scaled bioreactor train for a hypothetical licensed decoy-receptor Fc-fusion protein produced in Chinese hamster ovary cells. The rationale separates demonstrated facts from sponsor assumptions, treats glycosylation as a process-sensitive quality attribute of the product class, and argues that a second qualified source removes a single point of failure. The RFP specifies a 2,000 L campaign with two engineering runs and three GMP validation lots, an orthogonal comparability panel, dependency-based milestones with an 18 to 20 month duration, a budget of USD 8.7 to 12.15 million, a weighted scoring framework, and the confidentiality and intellectual property protections to put in place before issuing the request.Keywords: request for proposal; Fc-fusion protein; technology transfer; comparability; glycosylation; ICH Q5E; process validation; CDMO

Zenodo (CERN European Organization for Nuclear Research)
Northeastern University (US)
Viral Infectious Diseases and Gene Expression in Insects
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Specifying a Second-Site GMP Drug Substance Technology Transfer for a Licensed Fc-Fusion Biologic: A Request-for-Proposal Framework for Comparability and Process Validation — Peivand Pirouzi, Perpetua Ulofu, et al. · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS